Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan

Abstract Background Carfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). Carfilzomib improves overall survival (OS) and progression‐free survival (PFS); however, treatment with carfilzomib results in a higher incidence of cardiovascula...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Hiromi Hagiwara, Takafumi Nakayama, Hiroya Hashimoto, Shigeru Kusumoto, Hidekatsu Fukuta, Takeshi Kamiya, Koichi Ikuta, Shinsuke Iida
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2023-10-01
Sarja:	Cancer Medicine
Aiheet:	carfilzomib large claims database lenalidomide multiple myeloma overall survival renal impairment
Linkit:	https://doi.org/10.1002/cam4.6457
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!